Identification_NN of_IN critical_JJ residues_NNS in_IN loop_NN E_NN in_IN the_DT 5-HT3ASR_NP binding_JJ site_NN Abstract_NP |_SYM Background_NN |_SYM The_DT serotonin_NN type_NN 3_CD receptor_NN (_( 5-HT3R_NP )_) is_VBZ a_DT member_NN of_IN a_DT superfamily_NN of_IN ligand_NN gated_VBD ion_NN channels_NNS ._SENT All_DT members_NNS of_IN this_DT family_NN share_NN a_DT large_JJ degree_NN of_IN sequence_NN homology_NN and_CC presumably_RB significant_JJ structural_JJ similarity_NN ._SENT A_DT large_JJ number_NN of_IN studies_NNS have_VBP explored_VBN the_DT structure-function_NN relationships_NNS of_IN members_NNS of_IN this_DT family_NN ,_, particularly_RB the_DT nicotinic_JJ and_CC GABA_NP receptors_NNS ._SENT This_DT information_NN can_MD be_VB utilized_VBN to_TO gain_VB additional_JJ insights_NNS into_IN specific_JJ structural_JJ and_CC functional_JJ features_NNS of_IN other_JJ receptors_NNS in_IN this_DT family_NN ._SENT Results_NNS |_SYM Thirteen_JJ amino_NN acids_NNS in_IN the_DT mouse_NN 5-HT3ASR_NN that_WDT correspond_VBP to_TO the_DT putative_JJ E_NN binding_VBG loop_NN of_IN the_DT nicotinic_JJ alpha7_JJ receptor_NN were_VBD chosen_VBN for_IN mutagenesis_NN ._SENT Due_JJ to_TO the_DT presence_NN of_IN a_DT highly_RB conserved_VBN glycine_NN in_IN this_DT region_NN ,_, it_PP has_VBZ been_VBN suggested_VBN that_IN this_DT binding_JJ loop_NN is_VBZ comprised_VBN of_IN a_DT hairpin_NN turn_NN and_CC may_MD form_VB a_DT portion_NN of_IN the_DT ligand-binding_JJ site_NN in_IN this_DT ion_NN channel_NN family_NN ._SENT Mutation_NN of_IN the_DT conserved_VBN glycine_NN (_( G147_JJ )_) to_TO alanine_NN eliminated_VBD binding_VBG of_IN the_DT 5-HT3R_JJ antagonist_NN [_SYM 3H]granisetron_JJ ._SENT Three_CD tyrosine_NN residues_NNS (_( Y140_NP ,_, Y142_NP and_CC Y152_NP )_) also_RB significantly_RB altered_VBN the_DT binding_NN of_IN 5-HT3R_NN ligands_NNS ._SENT Mutations_NNS in_IN neighboring_JJ residues_NNS had_VBD little_JJ or_CC no_DT effect_NN on_IN binding_VBG of_IN these_DT ligands_NNS to_TO the_DT 5-HT3ASR_NN ._SENT Conclusion_NN |_SYM Our_JJ data_NNS supports_VBZ a_DT role_NN for_IN the_DT putative_JJ E-loop_NP region_NN of_IN the_DT 5-HT3R_NN in_IN the_DT binding_NN of_IN 5-HT_NN ,_, mCPBG_NN ,_, d-tc_NN and_CC lerisetron_NN ._SENT 5-HT_JJ and_CC mCPBG_NN interact_VBP with_IN Y142_NP ,_, d-tc_NN with_IN Y140_NP and_CC lerisetron_NN with_IN both_DT Y142_NP and_CC Y152_NP ._SENT Our_PP$ data_NN also_RB provides_VBZ support_NN for_IN the_DT hypothesis_NN that_IN this_DT region_NN of_IN the_DT receptor_NN is_VBZ present_JJ in_IN a_DT loop_NN structure_NN ._SENT Sequence_NN homology_NN between_IN the_DT serotonin_NN type_NN 3_CD receptor_NN (_( 5-HT3R_NP )_) ,_, the_DT nicotinic_JJ acetylcholine_NN receptor_NN (_( nAChR_NP )_) ,_, the_DT GABAA_NP receptor_NN and_CC the_DT glycine_NN receptor_NN suggests_VBZ a_DT large_JJ amount_NN of_IN structural_JJ similarity_NN within_IN this_DT superfamily_NN of_IN ligand_NN gated_VBD ion_NN channels_NNS ._SENT This_DT presumed_JJ structural_JJ homology_NN can_MD be_VB used_VBN to_TO guide_VB site_NN directed_VBN mutagenesis_NN studies_NNS of_IN particular_JJ receptor_NN subtypes_NNS ._SENT On_IN a_DT gross_JJ level_NN ,_, all_DT members_NNS of_IN this_DT superfamily_NN assemble_VB as_IN pentameric_JJ receptors_NNS ._SENT In_IN some_DT cases_NNS ,_, receptors_NNS can_MD be_VB assembled_VBN from_IN a_DT single_JJ subunit_NN (_( 5-HT3AR_JJ and_CC nicotinic_JJ alpha7_JJ receptors_NNS )_) [_SYM ,-_NN ]_SYM ._SENT In_IN other_JJ cases_NNS ,_, at_IN least_JJS two_CD different_JJ subunits_NN are_VBP required_VBN ._SENT The_DT ligand_NN binding_VBG site_NN is_VBZ thought_VBN to_TO be_VB formed_VBN at_IN the_DT junction_NN between_IN two_CD subunits_NN ._SENT Based_VBN on_IN data_NNS obtained_VBN from_IN affinity_NN labeling_VBG and_CC site_NN directed_VBD mutagenesis_NN studies_NNS ,_, several_JJ regions_NNS of_IN the_DT nicotinic_JJ acetylcholine_NN receptor_NN have_VBP been_VBN implicated_VBN in_IN ligand_NN binding_NN ._SENT Six_CD essential_JJ loops_NNS appear_VBP to_TO contribute_VB to_TO the_DT binding_JJ site_NN with_IN the_DT position_NN of_IN each_DT loop_NN differing_VBG slightly_RB depending_VBG on_IN whether_IN the_DT receptor_NN is_VBZ heteromeric_JJ or_CC homomeric_JJ ._SENT For_IN homomeric_JJ receptors_NNS such_JJ as_IN the_DT alpha7_JJ nAChR_NN ,_, the_DT loops_NNS are_VBP identified_VBN as_IN A_NP ,_, B_NP ,_, C_NP ,_, D_NP ,_, E_NP and_CC F_NP ._SENT The_DT amino_NN acids_NNS that_WDT interact_VBP with_IN ligands_NNS presumably_RB extend_VBP into_IN the_DT binding_JJ site_NN from_IN these_DT loops_NNS ._SENT Subunits_NN are_VBP composed_VBN of_IN 2_CD faces_NNS (_( +_SYM and_CC -_: )_) with_IN the_NP +_SYM face_NN of_IN one_CD subunit_NN forming_VBG one_CD side_NN of_IN the_DT binding_JJ site_NN and_CC the_DT --_: face_VB of_IN another_DT subunit_NN forming_VBG the_DT complimentary_JJ side_NN ._SENT Some_DT binding_JJ loops_NNS (_( A_NP ,_, B_NP and_CC C_NP )_) are_VBP present_JJ on_IN the_DT --_: face_VB while_IN the_DT remaining_VBG loops_NNS (_( D_NP and_CC E_NP )_) are_VBP present_JJ on_IN the_NP +_SYM face_NN ._SENT ._SENT The_DT individual_JJ amino_NN acids_NNS that_WDT form_VBP binding_JJ interactions_NNS with_IN the_DT functional_JJ groups_NNS present_JJ on_IN a_DT ligand_NN are_VBP likely_JJ to_TO differ_VB for_IN each_DT receptor_NN subtype_NN ,_, reflecting_VBG the_DT specificity_NN of_IN a_DT particular_JJ binding_JJ site_NN ,_, however_RB ,_, the_DT overall_JJ structure_NN of_IN the_DT binding_JJ domain_NN may_MD be_VB similar_JJ even_RB for_IN binding_VBG sites_NNS with_IN different_JJ ligand_NN specificities_NNS ._SENT Identification_NN of_IN ligand_NN specificity_NN requires_VBZ identification_NN of_IN both_CC the_DT location_NN or_CC structure_NN of_IN individual_JJ binding_JJ site_NN loops_NNS and_CC the_DT amino_NN acids_NNS present_JJ in_IN a_DT particular_JJ receptor_NN subtype_NN ._SENT The_DT purpose_NN of_IN this_DT study_NN is_VBZ to_TO extend_VB the_DT information_NN available_JJ from_IN other_JJ members_NNS of_IN this_DT receptor_NN family_NN to_TO the_DT 5-HT3R_NN ._SENT Sequence_NN homology_NN and_CC a_DT presumed_JJ structural_JJ similarity_NN to_TO other_JJ ligand_NN gated_VBD ion_NN channels_NNS suggests_VBZ that_IN the_DT E_NP loop_NN region_NN of_IN the_DT 5-HT3AR_JJ forms_NNS part_NN of_IN the_DT ligand_NN binding_VBG domain_NN for_IN 5-HT3R_NN ligands_NNS ._SENT This_DT region_NN extends_VBZ from_IN Y140_NP to_TO K153_NP and_CC is_VBZ shown_VBN in_IN Table_NP ._SENT The_DT homologous_JJ sequences_NNS of_IN other_JJ representative_JJ members_NNS of_IN this_DT family_NN are_VBP also_RB shown_VBN ._SENT In_IN the_DT center_NN of_IN this_DT region_NN is_VBZ a_DT critical_JJ glycine_NN residue_NN that_WDT is_VBZ thought_VBN to_TO play_VB a_DT role_NN in_IN establishing_VBG a_DT hairpin_NN loop_NN ._SENT Recent_JJ x-ray_NN crystallographic_JJ data_NNS obtained_VBN from_IN an_DT ACh_JJ binding_JJ protein_NN (_( AChBP_NP )_) shows_VBZ a_DT loop_NN structure_NN in_IN this_DT region_NN resulting_VBG from_IN a_DT 3_CD residue_NN turn_NN containing_VBG a_DT glycine_NN homologous_JJ to_TO G147_JJ of_IN the_DT 5-HT3R_NN ._SENT On_IN either_DT side_NN of_IN this_DT putative_JJ turn_NN region_NN are_VBP residues_NNS that_WDT have_VBP been_VBN identified_VBN as_RB important_JJ to_TO receptor_NN binding_NN ._SENT The_DT formation_NN of_IN this_DT loop_NN structure_NN brings_VBZ amino_NN acids_NNS on_IN either_DT side_NN of_IN glycine_NN into_IN close_JJ proximity_NN and_CC may_MD form_VB a_DT binding_JJ pocket_NN that_WDT will_MD accommodate_VB one_CD or_CC more_JJR functional_JJ groups_NNS ._SENT In_IN order_NN to_TO identify_VB the_DT interaction_NN of_IN amino_NN acids_NNS in_IN this_DT binding_JJ loop_NN with_IN 5-HT3R_NN ligands_NNS ,_, we_PP have_VBP constructed_VBN alanine_NN mutations_NNS of_IN residues_NNS throughout_IN this_DT region_NN and_CC evaluated_VBD the_DT alteration_NN in_IN binding_JJ affinity_NN of_IN 5_CD different_JJ classes_NNS of_IN 5-HT3R_NN ligands_NNS ._SENT Our_PP$ data_NN identifies_VBZ 3_CD tyrosine_NN residues_NNS that_WDT appear_VBP to_TO interact_VB selectively_RB with_IN each_DT structural_JJ class_NN and_CC supports_VBZ the_DT existence_NN of_IN a_DT loop_NN structure_NN in_IN this_DT region_NN of_IN the_DT receptor_NN ._SENT Figure_NP 1_CD |_SYM 5-HT3R_NN ligands_NNS ._SENT 5-HT3R_NP ligands_NNS ._SENT Table_NP 1_CD |_SYM Sequence_NP Comparison_NP of_IN Putative_NP Binding_NP Loop_NP Region_NP ._SENT All_DT mutant_JJ receptors_NNS were_VBD tested_VBN for_IN their_PP$ ability_NN to_TO bind_VB the_DT 5-HT3R_JJ antagonist_NN [_SYM 3H]granisetron_JJ ._SENT Table_NN shows_VBZ the_DT Kd_NN values_VBZ for_IN wildtype_NN mouse_NN 5-HT3ASRs_NN and_CC the_DT 13_CD alanine_NN mutations_NNS we_PP evaluated_VBD ._SENT [_SYM 3H]granisetron_JJ is_VBZ a_DT potent_JJ antagonist_NN of_IN the_DT wt_NP 5-HT3R_NP (_( Kd_NP =_SYM 0.98_CD +-_NN 0.12_CD nM_NN )_) ._SENT This_DT value_NN agrees_VBZ with_IN published_VBN data_NNS for_IN this_DT compound_NN ._SENT Bmax_NN values_NNS range_VBP from_IN the_DT 5.5_CD pmoles/mg_NN protein_NN observed_VBD for_IN E148A_NP to_TO 0.30_CD pmoles/mg_NN protein_NN for_IN the_DT K153A_NP mutation_NN ,_, indicating_VBG some_DT variability_NN in_IN expression_NN of_IN the_DT different_JJ receptors_NNS ._SENT In_IN general_JJ ,_, however_RB ,_, receptor_NN expression_NN was_VBD similar_JJ to_TO that_DT reported_VBN by_IN other_JJ laboratories_NNS [_SYM ,-_NN ]_SYM ._SENT No_DT detectable_JJ binding_NN was_VBD observed_VBN for_IN G147A_NP and_CC V149A_NP mutant_JJ receptors_NNS ._SENT For_IN all_DT other_JJ mutants_NNS ,_, decreases_NNS in_IN binding_JJ affinity_NN (_( increased_VBN Kd_NP )_) were_VBD observed_VBN although_IN the_DT magnitude_NN of_IN the_DT change_NN was_VBD less_JJR than_IN 10_CD fold_NN in_IN all_DT cases_NNS ._SENT A_DT bar_NN graph_NN showing_VBG the_DT change_NN in_IN Kd_NP value_NN resulting_VBG from_IN each_DT alanine_NN mutation_NN is_VBZ shown_VBN in_IN Figure_NP ._SENT The_DT largest_JJS decreases_NNS in_IN binding_JJ affinity_NN were_VBD observed_VBN for_IN Y142A_NP (_( 4.6_CD fold_NN ,_, Figure_NP )_) ,_, E148A_NP (_( 5.3_CD fold_NN )_) and_CC Q150A_NP --_: K153A_NP (_( 6_CD --_: 8_CD fold_NN )_) ._SENT Figure_NP 2_CD |_SYM Changes_NP in_IN Ki_NP or_CC Kd_NP (_( for_IN binding_VBG of_IN [_SYM 3H]granisetron_JJ )_) as_IN a_DT result_NN of_IN alanine_NN mutations_NNS ._SENT Changes_NNS in_IN Ki_NP or_CC Kd_NP (_( for_IN binding_VBG of_IN [_SYM 3H]granisetron_JJ )_) as_IN a_DT result_NN of_IN alanine_NN mutations_NNS ._SENT The_DT values_NNS shown_VBN are_VBP the_DT ratio_NN of_IN the_DT Kd_NP or_CC Ki_NP for_IN wildtype_NN and_CC mutant_JJ receptors_NNS ._SENT The_DT length_NN of_IN each_DT bar_NN illustrates_VBZ the_DT magnitude_NN of_IN change_NN in_IN either_CC the_DT Kd_NP or_CC Ki_NP relative_JJ to_TO wildtype_NN while_IN the_DT direction_NN indicates_VBZ an_DT increase_NN (_( up_RB )_) or_CC decrease_VB (_( down_RB )_) in_IN the_DT Kd_NP or_CC Ki_NP ._SENT A._LS Most_JJS alanine_NN mutations_NNS produced_VBD little_JJ change_NN in_IN Kd_NP ._SENT No_DT binding_NN was_VBD detected_VBN for_IN the_DT G147A_NP and_CC V149A_NP receptors_NNS therefore_RB no_DT Kd_NN could_MD be_VB determined_VBN ._SENT B._NP Changes_NP in_IN Ki_NP were_VBD small_JJ for_IN most_JJS receptors_NNS although_IN large_JJ changes_NNS were_VBD observed_VBN for_IN select_JJ ligands_NNS at_IN Y140A_NP ,_, Y142A_NP and_CC Y152A_NP receptors_NNS ._SENT The_DT relative_JJ increases_NNS in_IN Ki_NP for_IN these_DT amino_NN acids_NNS are_VBP as_RB follows_VBZ :_: 5-HT_NN :_: Y140A_NP 1.3_CD +-_NN 0.30_CD fold_NN ,_, Y142A_NP 110_CD +-_NN 25_CD fold_NN ,_, Y152A_NP 24_CD +-_NN 5.6_CD fold_NN mCPBG_NN :_: Y140A_NP 7.3_CD +-_NN 1.7_CD fold_NN ,_, Y142A_NP 160_CD +-_NN 36_CD fold_NN ,_, Y152A_NP 24_CD +-_NN 5.6_CD fold_NN d-tc_NN :_: Y140A_NP 50_CD +-_NN 12_CD fold_NN ,_, Y142A_NP 6.5_CD +-_NN 1.5_CD ,_, Y152A_NP 10.0_CD +-_NN 2.3_CD fold_NN lerisetron_NN :_: Y140A_NP 4.6_CD +-_NN 1.1_CD fold_NN ,_, Y142A_NP 160_CD +-_NN 37_CD fold_NN ,_, Y152A_NP 190_CD +-_NN 43_CD fold_NN Figure_NP 3_CD |_SYM Saturation_NN binding_VBG isotherms_NNS for_IN binding_VBG of_IN [_SYM 3H]granisetron_JJ to_TO wildtype_NN ,_, Y140A_NP ,_, Y142A_NP and_CC Y152A_NP receptors_NNS ._SENT Saturation_NN binding_VBG isotherms_NNS for_IN binding_VBG of_IN [_SYM 3H]granisetron_JJ to_TO wildtype_NN ,_, Y140A_NP ,_, Y142A_NP and_CC Y152A_NP receptors_NNS ._SENT The_DT data_NNS shown_VBN represent_VBP the_DT specific_JJ binding_NN of_IN [_SYM 3H]granisetron_JJ as_IN determined_VBN from_IN at_IN least_JJS four_CD identical_JJ experiments_NNS ._SENT Specific_JJ binding_NN was_VBD determined_VBN as_IN the_DT fraction_NN of_IN total_JJ binding_NN not_RB inhibited_VBD by_IN a_DT saturating_VBG concentration_NN of_IN mCPBG_NP or_CC MDL-72222_NP ._SENT Data_NNS were_VBD combined_VBN and_CC fitted_VBN using_VBG non-linear_JJ curve_NN fitting_NN ._SENT Only_JJ small_JJ shifts_NNS in_IN binding_JJ affinity_NN to_TO [_SYM 3H]granisetron_JJ were_VBD observed_VBN on_IN all_DT three_CD mutants_NNS ._SENT Kd_NN values_NNS ,_, Bmax_NP and_CC Hill_NP coefficients_NNS are_VBP shown_VBN in_IN Table_NP ._SENT Table_NP 2_CD |_SYM [_SYM 3H]Granisetron_JJ binding_NN to_TO wildtype_NN and_CC mutant_JJ 5-HT3ASRs_NN ._SENT Inhibition_NN binding_NN assays_NNS were_VBD also_RB conducted_VBN ._SENT Four_CD test_NN compounds_NNS with_IN structures_NNS representative_JJ of_IN the_DT major_JJ classes_NNS of_IN 5-HT3R_NN ligands_NNS were_VBD chosen_VBN :_: serotonin_NN (_( 5-HT_JJ ,_, the_DT endogenous_JJ agonist_NN )_) ,_, m-chlorophenylbiguanide_NN (_( mCPBG_NN ,_, agonist_NN )_) ,_, d-tubocurarine_NP (_( d-tc_NP ,_, antagonist_NN )_) and_CC lerisetron_NN (_( antagonist_NN )_) ._SENT The_DT Ki_NP values_NNS for_IN inhibition_NN of_IN [_SYM 3H]granisetron_JJ binding_NN by_IN all_DT four_CD compounds_NNS are_VBP shown_VBN in_IN Table_NP ._SENT Little_JJ change_NN in_IN Ki_NP value_NN was_VBD observed_VBN for_IN the_DT majority_NN of_IN mutations_NNS ._SENT The_DT values_NNS highlighted_VBN in_IN bold_JJ in_IN Table_NP represent_VBP the_DT Ki_NP values_NNS for_IN inhibition_NN of_IN [_SYM 3H]granisetron_JJ binding_NN on_IN mutant_JJ receptors_NNS that_WDT increased_VBD over_IN 10_CD fold_NN compared_VBN to_TO the_DT Ki_NP obtained_VBD for_IN wildtype_NN receptors_NNS ._SENT The_DT bar_NN chart_NN in_IN Figure_NP illustrates_VBZ the_DT changes_NNS in_IN Ki_NP resulting_VBG from_IN each_DT mutation_NN on_IN the_DT test_NN compounds_NNS ._SENT Ratios_NNS of_IN Ki_NP are_VBP shown_VBN as_IN positive_JJ for_IN increases_NNS in_IN Ki_NP on_IN mutant_JJ receptors_NNS versus_IN wildtype_NN and_CC negative_JJ for_IN decreases_NNS ._SENT A_DT positive_JJ change_NN thus_RB corresponds_VBZ to_TO a_DT decrease_NN in_IN binding_JJ affinity_NN for_IN the_DT compound_NN as_IN a_DT result_NN of_IN the_DT mutation_NN ._SENT Large_JJ decreases_NNS in_IN binding_JJ affinity_NN were_VBD observed_VBN for_IN select_JJ compounds_NNS only_RB on_IN the_DT Y140A_NP ,_, Y142A_NP and_CC Y152A_NP mutations_NNS ._SENT Table_NP 3_CD |_SYM Ki_NP values_NNS for_IN Inhibition_NP of_IN [_SYM 3_CD H]granisetron_NP binding_VBG to_TO wildtype_NN and_CC mutant_JJ 5-HT3ASRs_NN ._SENT A_DT more_RBR detailed_JJ analysis_NN of_IN the_DT competition_NN binding_VBG data_NNS obtained_VBN for_IN the_DT Y140A_NP ,_, Y142A_NP and_CC Y152A_NP mutations_NNS is_VBZ shown_VBN in_IN Figure_NP ._SENT For_IN 5-HT_NN ,_, the_DT Y142A_NP mutation_NN produced_VBD a_DT 110_CD fold_NN increase_NN in_IN Ki_NP and_CC Y152A_NP produced_VBD a_DT 24_CD fold_NN increase_NN ._SENT No_DT change_NN in_IN Ki_NP was_VBD observed_VBN for_IN the_DT Y140A_NP mutation_NN ._SENT The_DT 5-HT3R_NP agonistmCPBG_NN showed_VBD a_DT similar_JJ profile_NN for_IN the_DT changes_NNS in_IN Ki_NP values_NNS resulting_VBG from_IN mutations_NNS of_IN the_DT three_CD tyrosines_NNS ._SENT As_RB was_VBD observed_VBN for_IN 5-HT_NN ,_, the_DT Y142A_NP mutation_NN produced_VBD a_DT large_JJ increase_NN in_IN Ki_NP (_( 160_CD fold_NN )_) while_IN the_DT Y14_NP 0A_NP and_CC Y152A_NP mutations_NNS produced_VBD only_RB 7_CD and_CC 24_CD fold_NN changes_NNS respectively_RB ._SENT Figure_NP 4_CD |_SYM Inhibition_NN of_IN [_SYM 3H]granisetron_JJ binding_NN by_IN 5-HT3R_NN ligands_NNS ._SENT Inhibition_NN of_IN [_SYM 3H]granisetron_JJ binding_NN by_IN 5-HT3R_NN ligands_NNS ._SENT The_DT data_NNS represent_VBP the_DT combined_JJ results_NNS of_IN at_IN least_JJS four_CD experiments_NNS ._SENT Assays_NNS were_VBD conducted_VBN as_IN described_VBN in_IN Materials_NPS and_CC Methods_NP ._SENT Fractional_JJ response_NN is_VBZ the_DT fraction_NN of_IN [_SYM 3H]granisetron_JJ binding_NN obtained_VBN in_IN the_DT presence_NN and_CC absence_NN of_IN inhibitor_NN ._SENT An_DT IC50_NP value_NN was_VBD determined_VBN from_IN the_DT data_NNS using_VBG non-linear_JJ curve_NN fitting_NN as_IN described_VBN in_IN the_DT methods_NNS and_CC the_DT Ki_NP value_NN calculated_VBD using_VBG the_DT Cheng-Prusoff_NP equation_NN ,_, the_DT Kd_NN as_IN determined_VBN in_IN Figure_NP and_CC the_DT concentration_NN of_IN ligand_NN used_VBN to_TO obtain_VB the_DT inhibition_NN data_NNS ._SENT Kd_NN values_NNS are_VBP reported_VBN in_IN Table_NP ._SENT A._NP 5-HT_JJ B._NP mCPBG_NN C._NP dtC_NP D._NP Lerisetron_NP The_DT Ki_NP value_NN for_IN d-tc_NN inhibition_NN of_IN [_SYM 3H]granisetron_JJ binding_NN was_VBD altered_VBN only_RB slightly_RB by_IN the_DT Y142A_NP or_CC Y152A_NP mutations_NNS (_( 6.5_CD fold_NN and_CC 10_CD fold_NN changes_NNS respectively_RB )_) ._SENT The_DT Y140A_NP mutation_NN ,_, however_RB ,_, produced_VBD a_DT 50_CD fold_NN increase_NN in_IN the_DT Ki_NP compared_VBN to_TO wildtype_NN receptors_NNS ._SENT The_DT Ki_NP value_NN for_IN lerisetron_NN inhibition_NN of_IN [_SYM 3H]granisetron_JJ binding_NN was_VBD increased_VBN 160_CD fold_NN by_IN the_DT Y142A_NP mutation_NN and_CC 190_CD fold_NN by_IN the_DT Y152A_NP mutation_NN ._SENT Only_RB a_DT 4.6_CD fold_NN change_NN in_IN Ki_NP resulted_VBD from_IN the_DT Y140A_NP mutation_NN ._SENT Lerisetron_NP was_VBD the_DT only_JJ compound_NN for_IN which_WDT a_DT large_JJ increase_NN in_IN the_DT Ki_NP was_VBD observed_VBN on_IN the_DT Y152A_NP mutation_NN ._SENT This_DT mutation_NN produced_VBD smaller_JJR changes_NNS in_IN Ki_NP for_IN 5-HT_NN and_CC mCPBG_NN (_( 24_CD fold_NN for_IN both_DT )_) and_CC only_RB a_DT 10_CD fold_NN change_NN for_IN d-tc_NP ._SENT In_IN whole_JJ cell_NN patch_NN clamp_NN studies_NNS ,_, 5-HT_JJ perfusion_NN of_IN cells_NNS transfected_VBN with_IN Y140A_NP and_CC Y142A_NP cDNA_NN produced_VBD no_DT responses_NNS at_IN 5-HT_JJ concentrations_NNS of_IN up_IN to_TO 1_CD mM_NNS although_IN specific_JJ binding_NN to_TO these_DT receptors_NNS was_VBD identified_VBN in_IN receptor_NN binding_VBG studies_NNS ._SENT Unlike_IN Y140A_NP and_CC Y142A_NP ,_, Y152A_NP receptors_NNS responded_VBD to_TO application_NN of_IN 5-HT_NN ._SENT Due_JJ to_TO the_DT low_JJ potency_NN of_IN 5-HT_NN on_IN these_DT receptors_NNS ,_, only_RB a_DT portion_NN of_IN the_DT concentration_NN response_NN curve_NN could_MD be_VB determined_JJ (_( up_RB to_TO 1_CD mM_NNS )_) ._SENT The_DT EC50_NP value_NN was_VBD estimated_VBN as_IN greater_JJR than_IN 370_CD muM_NN ._SENT This_DT value_NN shows_VBZ a_DT greater_JJR than_IN 140_CD fold_NN increase_NN in_IN EC50_NP compared_VBN to_TO wildtype_NN receptors_NNS ;_: a_DT larger_JJR change_NN than_IN was_VBD observed_VBN for_IN the_DT Ki_NP (_( 24_CD fold_NN )_) ._SENT The_DT most_RBS dramatic_JJ change_NN observed_VBN for_IN whole_JJ cell_NN currents_NNS was_VBD an_DT alteration_NN in_IN the_DT kinetics_NN of_IN the_DT response_NN elicited_VBN by_IN application_NN of_IN 5-HT_NN ._SENT Y152A_NP mutant_JJ receptors_NNS displayed_VBD much_RB slower_JJR rise_NN times_NNS compared_VBN to_TO wildtype_NN receptors_NNS at_IN all_DT concentrations_NNS tested_VBD ._SENT Peak_JJ wt_NN responses_NNS were_VBD typically_RB obtained_VBN in_IN less_JJR than_IN 80_CD ms_NNS while_IN Y152A_NP responses_NNS required_VBD several_JJ seconds_NNS to_TO plateau_NN ._SENT Desensitization_NN kinetics_NNS were_VBD also_RB altered_VBN ._SENT While_IN wt_NN receptors_NNS desensitized_VBD rapidly_RB ,_, mutant_JJ receptors_NNS showed_VBD no_DT desensitization_NN during_IN the_DT 8_CD s_NN perfusion_NN time_NN ._SENT Figure_NP 5_CD |_SYM Whole_NP cell_NN patch_NN clamp_NN recording_NN from_IN tsA_NN 201_CD cells_NNS transfected_VBN with_IN wildtype_NN and_CC Y152A_NP cDNA_NN ._SENT Whole_JJ cell_NN patch_NN clamp_NN recording_NN from_IN tsA_NN 201_CD cells_NNS transfected_VBN with_IN wildtype_NN and_CC Y152A_NP cDNA_NN ._SENT Data_NNS were_VBD obtained_VBN using_VBG whole_JJ cell_NN patch_NN clamp_NN on_IN tsA201_NN cells_NNS transfected_VBN with_IN wt_NP or_CC Y152A_NP mutant_JJ 5-HT3ASR_NN cDNA_NN ._SENT Cells_NNS were_VBD clamped_VBN at_IN a_DT holding_NN potential_NN of_IN -60_CD mV_NN and_CC 5-HT_NN applied_VBN with_IN a_DT rapid_JJ perfusion_NN system_NN ._SENT The_DT application_NN time_NN for_IN 5-HT_NN is_VBZ indicated_VBN by_IN the_DT bar_NN above_IN the_DT curves_NNS ._SENT The_DT responses_NNS indicated_VBN in_IN A_NP and_CC B_NP are_VBP representative_JJ examples_NNS of_IN at_IN least_JJS 4_CD sets_NNS of_IN experiments_NNS ._SENT A._NP Wildtype_NP 5-HT3ASR_NP ._SENT 5-HT_NN was_VBD applied_VBN as_IN indicated_VBN for_IN a_DT 4_CD s_NN duration_NN ._SENT The_DT concentrations_NNS of_IN 5-HT_JJ used_VBN and_CC the_DT response_NN amplitudes_NNS are_VBP :_: a._NP 0.3_CD muM_NN (_( 0.03_CD nA_NN )_) b._NP 1.0_CD muM_NN (_( 0.96_CD nA_NN )_) c._FW 3.0_CD muM_NN (_( 2.5_CD nA_NN )_) d._NP 30.0_CD muM_NN (_( 4.4_CD nA_NN )_) ,_, e._FW 100.0_CD muM_NN (_( 3.9_CD nA_NN )_) ._SENT B._NP Y152A_NP mutant_JJ receptors_NNS ._SENT 5-HT_NN was_VBD applied_VBN as_IN indicated_VBN for_IN an_DT 8_CD s_NN duration_NN ._SENT The_DT curves_NNS in_IN B_NP were_VBD offset_VBN vertically_RB for_IN clarity_NN ._SENT The_DT dashed_VBN line_NN in_IN each_DT curve_NN indicates_VBZ the_DT baseline_JJ level_NN for_IN that_DT response_NN ._SENT The_DT concentrations_NNS of_IN 5-HT_JJ used_VBN and_CC the_DT response_NN amplitudes_NNS are_VBP :_: f._NP 3.0_CD muM_NN (_( 0.10_CD nA_NN )_) g._FW 100_CD muM_NN (_( 0.14_CD nA_NN )_) h._NP 300.0_CD muM_NN (_( 0.57_CD nA_NN )_) i._FW 1.0_CD mM_NNS (_( 1.0_CD nA_NN )_) ._SENT C._NP Concentration_NP response_NN curve_NN for_IN 5-HT_JJ activation_NN of_IN wt_NN 5-HT3ASRs_NN ._SENT Each_DT data_NNS point_NN represents_VBZ the_DT combined_JJ results_NNS of_IN 4_CD experiments_NNS ._SENT Responses_NNS were_VBD normalized_VBN to_TO the_DT response_NN obtained_VBN at_IN 30_CD muM_NN and_CC the_DT curves_NNS fit_VBP as_IN described_VBN in_IN the_DT methods_NNS section_NN ._SENT EC50_NN =_SYM 2.7_CD +-_NN 0.25_CD muM_NN ,_, n_NN =_SYM 1.6_CD +-_NN 0.22_CD ._SENT D._NP Concentration_NP response_NN curve_NN for_IN 5-HT_JJ activation_NN of_IN Y152A_NP 5-HT3ASRs_NN ._SENT Each_DT data_NNS point_NN represents_VBZ the_DT combined_JJ results_NNS of_IN 4_CD experiments_NNS ._SENT The_DT response_NN did_VBD not_RB plateau_NN in_IN the_DT range_NN of_IN concentrations_NNS used_VBN and_CC hence_RB responses_NNS were_VBD normalized_VBN to_TO the_DT maximum_JJ concentration_NN of_IN 5-HT_JJ (_( 1_CD mM_NNS )_) ._SENT The_DT EC50_NP was_VBD estimated_VBN by_IN fitting_VBG the_DT data_NNS to_TO the_DT following_VBG equation_NN :_: I_PP =_SYM Imax/(1_JJ +(EC50/_NN [_SYM C])n_NP )_) ,_, where_WRB is_VBZ the_DT normalized_VBN current_JJ at_IN 5-HT_JJ concentration_NN [_SYM C_NP ]_SYM ,_, EC50_NP is_VBZ the_DT concentration_NN of_IN 5-HT_NN needed_VBN to_TO obtain_VB half_DT maximal_JJ activation_NN and_CC n_NN is_VBZ the_DT apparent_JJ Hill_NP coefficient_NN ._SENT Imax_NP in_IN this_DT case_NN represents_VBZ the_DT estimated_JJ maximum_JJ current_JJ relative_NN to_TO the_DT response_NN obtained_VBN at_IN 1_CD mM_NNS ._SENT To_TO obtain_VB the_DT curve_NN shown_VBN in_IN the_DT figure_NN ,_, the_DT Hill_NP coefficient_NN was_VBD fixed_VBN at_IN the_DT wt_JJ value_NN of_IN 1.6_CD ._SENT The_DT EC50_NP value_NN obtained_VBN from_IN this_DT fit_NN is_VBZ 370_CD +-_NN 27_CD muM_NN ._SENT The_DT putative_JJ E-loop_NP region_NN of_IN the_DT LGIC_JJ family_NN of_IN receptors_NNS is_VBZ homologous_JJ to_TO residues_NNS Y140_NP through_IN K153_NP in_IN the_DT 5-HT3R_NN [_SYM ,-_NN ]_SYM ._SENT Structure-function_NN studies_NNS of_IN this_DT region_NN have_VBP been_VBN conducted_VBN in_IN several_JJ other_JJ members_NNS of_IN this_DT family_NN of_IN receptors_NNS including_VBG GABAA_NP and_CC nAChR_NP subtypes_NNS ._SENT In_IN each_DT case_NN ,_, residues_NNS have_VBP been_VBN identified_VBN that_WDT alter_VBP either_CC the_DT binding_NN of_IN selective_JJ ligands_NNS or_CC receptor_NN function_NN [_SYM ,-_NN ]_SYM ._SENT In_IN order_NN to_TO determine_VB if_IN this_DT loop_NN also_RB contains_VBZ residues_NNS critical_JJ to_TO the_DT structure_NN or_CC function_NN of_IN the_DT 5-HT3R_NN ,_, we_PP have_VBP constructed_VBN alanine_NN mutations_NNS of_IN amino_NN acids_NNS throughout_IN the_DT homologous_JJ region_NN of_IN the_DT mouse_NN 5-HT3ASR_NN and_CC investigated_VBD the_DT affects_NNS on_IN binding_VBG of_IN 5_CD different_JJ structural_JJ classes_NNS of_IN 5-HT3R_NN ligands_NNS ._SENT We_PP have_VBP identified_VBN three_CD tyrosine_NN residues_NNS that_WDT appear_VBP to_TO play_VB a_DT role_NN in_IN binding_VBG of_IN selective_JJ ligands_NNS to_TO this_DT receptor_NN ._SENT In_IN addition_NN ,_, our_PP$ data_NNS support_VBP the_DT existence_NN of_IN a_DT loop_NN structure_NN in_IN this_DT region_NN as_RB has_VBZ been_VBN hypothesized_VBN for_IN the_DT nAChR_NN and_CC identified_VBN in_IN a_DT homologous_JJ AChBP_NP ._SENT Representative_JJ members_NNS of_IN 5_CD major_JJ structural_JJ classes_NNS of_IN 5-HT3R_NN ligands_NNS were_VBD tested_VBN on_IN all_DT mutants_NNS ._SENT These_DT ligands_NNS include_VBP the_DT antagonists_NNS [_SYM 3H]granisetron_JJ ,_, d-tc_NN and_CC lerisetron_NN ,_, and_CC the_DT agonists_NNS 5-HT_NN and_CC mCPBG_NN ._SENT Most_JJS of_IN the_DT mutations_NNS tested_VBD produced_VBN only_RB minor_JJ changes_NNS in_IN binding_JJ affinity_NN for_IN these_DT ligands_NNS ._SENT Large_JJ changes_NNS in_IN binding_VBG are_VBP only_RB apparent_JJ on_IN Y140A_NP ,_, Y142A_NP and_CC Y152A_NP receptors_NNS for_IN select_JJ ligands_NNS ._SENT The_DT resulting_VBG effects_NNS of_IN individual_JJ mutations_NNS are_VBP specific_JJ to_TO particular_JJ structural_JJ classes_NNS of_IN ligands_NNS ._SENT The_DT Y140A_NP mutation_NN altered_VBD the_DT Ki_NP for_IN d-tc_NP inhibition_NN ,_, but_CC did_VBD not_RB alter_VB the_DT Ki_NP obtained_VBD for_IN any_DT other_JJ compound_NN tested_VBD ,_, while_IN Y142A_NP altered_VBD the_DT Ki_NP for_IN mCPBG_NN ,_, 5-HT_NN and_CC lerisetron_NN but_CC had_VBD little_JJ if_IN any_DT effect_NN on_IN inhibition_NN by_IN d-tc_NP ._SENT These_DT data_NNS indicate_VBP the_DT highly_RB specific_JJ nature_NN of_IN the_DT effects_NNS introduced_VBN by_IN the_DT alanine_NN mutations_NNS and_CC appear_VBP to_TO reflect_VB specific_JJ changes_NNS in_IN ligand/receptor_NN interaction_NN ._SENT Binding_VBG of_IN [_SYM 3H]granisetron_JJ is_VBZ altered_VBN only_RB slightly_RB by_IN the_DT alanine_NN mutations_NNS introduced_VBN in_IN this_DT study_NN (_( <10_JJ fold_NN )_) ._SENT This_DT result_NN indicates_VBZ the_DT lack_NN of_IN involvement_NN of_IN amino_NN acids_NNS in_IN this_DT binding_JJ loop_NN in_IN the_DT binding_JJ of_IN [_SYM 3H]granisetron_JJ ._SENT It_PP is_VBZ apparent_JJ ,_, however_RB ,_, that_IN [_SYM 3H]granisetron_JJ does_VBZ occupy_VB the_DT same_JJ binding_JJ cleft_NN as_IN other_JJ 5-HT3R_NN ligands_NNS as_RB evidenced_VBN by_IN the_DT ability_NN of_IN 5-HT_NN ,_, mCPBG_NN ,_, d-tc_NN and_CC lerisetron_NN to_TO displace_VB it_PP from_IN the_DT binding_JJ site_NN ._SENT The_DT lack_NN of_IN any_DT large_JJ change_NN in_IN binding_VBG of_IN granisetron_NN supports_VBZ our_PP$ contention_NN that_IN there_EX is_VBZ little_RB global_JJ structural_JJ perturbation_NN of_IN the_DT binding_JJ site_NN resulting_VBG from_IN the_DT introduction_NN of_IN each_DT individual_JJ alanine_NN mutation_NN ._SENT The_DT Ki_NP for_IN inhibition_NN of_IN [_SYM 3H]granisetron_JJ binding_NN by_IN 5-HT_NN was_VBD increased_VBN 110_CD fold_NN by_IN the_DT Y142A_NP mutation_NN ._SENT A_DT similar_JJ increase_NN was_VBD also_RB observed_VBN for_IN mCPBG_NN (_( 160_CD fold_NN )_) ._SENT In_IN contrast_NN ,_, the_DT Y140A_NP and_CC Y152A_NP mutations_NNS produced_VBD relatively_RB small_JJ changes_NNS in_IN the_DT Ki_NP ._SENT Since_IN both_DT compounds_NNS are_VBP 5-HT3R_NN agonists_NNS ,_, they_PP are_VBP likely_JJ to_TO share_VB the_DT same_JJ binding_JJ interactions_NNS ._SENT One_CD of_IN these_DT interactions_NNS appears_VBZ to_TO be_VB with_IN Y142_NP ._SENT Other_JJ studies_NNS have_VBP also_RB identified_VBN binding_JJ site_NN interactions_NNS for_IN agonists_NNS ._SENT R91_NP ,_, E106_NP ,_, F107_NP ,_, W183_NP and_CC several_JJ residues_NNS adjacent_JJ to_TO the_DT M1_JJ region_NN have_VBP all_RB been_VBN demonstrated_VBN to_TO alter_VB the_DT action_NN of_IN 5-HT_NN and/or_CC mCPBG_NN ._SENT Within_IN the_DT crystal_NN structure_NN of_IN the_DT AChBP_NP ,_, homologous_JJ residues_NNS are_VBP located_VBN in_IN the_DT apparent_JJ binding_JJ site_NN ._SENT The_DT effects_NNS of_IN agonist_NN on_IN the_DT 5-HT3R_NP are_VBP mediated_VBN by_IN their_PP$ interaction_NN with_IN these_DT binding_JJ site_NN residues_NNS ,_, resulting_VBG in_IN stable_JJ receptor_NN conformations_NNS ,_, including_VBG the_DT channel_NN open_JJ state_NN ._SENT Identification_NN of_IN interacting_VBG amino_NN acids_NNS and_CC their_PP$ location_NN in_IN the_DT tertiary_JJ structure_NN of_IN the_DT receptor_NN may_MD provide_VB clues_NNS to_TO the_DT mechanism_NN of_IN channel_NN opening_NN ._SENT For_IN example_NN ,_, amino_NN acids_NNS homologous_JJ to_TO Y142_NP and_CC W183_NP (_( R104_NP and_CC W143_NP respectively_RB )_) are_VBP in_IN close_JJ proximity_NN in_IN the_DT AChBP_NP ,_, although_IN on_IN complementary_JJ faces_NNS of_IN the_DT receptor_NN subunits_NN ._SENT Spier_NP et_FW ._SENT al._FW have_VBP suggested_VBN that_IN W183_NP may_MD be_VB involved_VBN in_IN a_DT cation-pi_NN interaction_NN with_IN the_DT amino_NN group_NN of_IN 5-HT_NN and_CC mCPBG_NN ._SENT If_IN W183_NP and_CC Y142_NP are_VBP located_VBN near_IN each_DT other_JJ but_CC on_IN opposite_JJ faces_NNS of_IN the_DT binding_JJ site_NN in_IN the_DT 5-HT3R_NN ,_, then_RB they_PP could_MD potentially_RB act_VB in_IN concert_NN to_TO help_VB stabilize_VB a_DT conformation_NN of_IN the_DT receptor_NN leading_VBG to_TO channel_VB opening_NN ._SENT d-Tubocurarine_NP inhibition_NN was_VBD uniquely_RB altered_VBN by_IN the_DT Y140A_NP mutation_NN ._SENT An_DT increase_NN in_IN Ki_NP of_IN 50_CD fold_NN was_VBD observed_VBN for_IN d-tc_NP on_IN this_DT mutant_NN ._SENT Little_RB if_IN any_DT change_NN resulted_VBD for_IN any_DT other_JJ mutation_NN ._SENT Thus_RB ,_, while_IN d-tc_NP may_MD form_VB an_DT interaction_NN with_IN the_DT receptor_NN at_IN this_DT binding_JJ loop_NN ,_, it_PP appears_VBZ to_TO interact_VB with_IN Y140_NP rather_RB than_IN Y142_NP or_CC Y152_NP ._SENT This_DT difference_NN in_IN binding_VBG site_NN interactions_NNS of_IN the_DT antagonist_NN d-tc_NN and_CC the_DT agonists_NNS 5-HT_NN and_CC mCPBG_NN could_MD be_VB the_DT result_NN of_IN a_DT slightly_RB different_JJ positioning_NN of_IN d-tc_NN in_IN the_DT binding_JJ site_NN ._SENT The_DT antagonists_NNS d-tc_NP and_NP [_SYM 3H]granisetron_JJ also_RB interact_VB differently_RB with_IN this_DT region_NN since_RB [_SYM 3H]granisetron_JJ binding_NN was_VBD not_RB altered_VBN by_IN mutations_NNS at_IN any_DT of_IN the_DT amino_NN acids_NNS tested_VBD ._SENT While_IN the_DT binding_NN of_IN d-tc_NP appears_VBZ to_TO involve_VB some_DT interaction_NN with_IN this_DT binding_JJ loop_NN ,_, the_DT binding_JJ of_IN [_SYM 3H]granisetron_JJ does_VBZ not_RB ._SENT Previous_JJ studies_NNS have_VBP indicated_VBN a_DT point_NN of_IN overlap_VB between_RB [_SYM 3H]granisetron_JJ and_CC d-tc_NN at_IN W89_NP of_IN the_DT 5-HT3ASR_NN ._SENT ._SENT These_DT studies_NNS indicate_VBP that_IN the_DT binding_JJ regions_NNS for_IN these_DT antagonists_NNS are_VBP partially_RB overlapping_VBG at_IN W89_NP but_CC not_RB at_IN Y140_NP ._SENT In_IN addition_NN to_TO Y140_NP and_CC W89_NP ,_, d-tc_NP has_VBZ also_RB been_VBN observed_VBN to_TO interact_VB with_IN D206_NP and_CC several_JJ other_JJ residues_NNS in_IN loop_NN C_NP ._SENT The_DT d-tc_NP binding_JJ site_NN appears_VBZ to_TO involve_VB interaction_NN with_IN at_IN least_JJS three_CD different_JJ binding_JJ loops_NNS (_( A_NP ,_, E_NP and_CC C_NP )_) although_IN additional_JJ interacting_VBG amino_NN acids_NNS may_MD be_VB found_VBN ._SENT Data_NNS obtained_VBN for_IN d-tc_NP is_VBZ particularly_RB valuable_JJ due_RB to_TO the_DT rigid_JJ nature_NN of_IN this_DT molecule_NN ._SENT Determination_NN of_IN interacting_VBG functional_JJ groups_NNS and_CC their_PP$ relationship_NN to_TO individual_JJ amino_NN acids_NNS could_MD enable_VB d-tc_NP to_TO be_VB used_VBN as_IN a_DT molecular_JJ ruler_NN to_TO determine_VB relative_JJ positions_NNS of_IN these_DT amino_NN acids_NNS ._SENT Lerisetron_NN inhibition_NN of_IN [_SYM 3H]granisetron_JJ binding_NN to_TO mutant_JJ receptors_NNS was_VBD also_RB investigated_VBN ._SENT Lerisetron_NP is_VBZ a_DT potent_JJ 5-HT3R_NN antagonist_NN first_RB synthesized_VBN by_IN Orales_NP et_FW ._SENT al._FW ._SENT As_RB was_VBD observed_VBN for_IN 5-HT3R_NN agonists_NNS ,_, lerisetron_NN binding_NN was_VBD altered_VBN by_IN the_DT Y142A_NP mutation_NN ._SENT This_DT mutation_NN produced_VBD an_DT increase_NN in_IN the_DT Ki_NP of_IN 160_CD fold_NN compared_VBN to_TO wildtype_NN receptors_NNS ._SENT This_DT increase_NN in_IN Ki_NP indicates_VBZ an_DT important_JJ interaction_NN of_IN lerisetron_NN with_IN Y142_NP and_CC a_DT similarity_NN between_IN the_DT binding_JJ location_NN of_IN lerisetron_NN ,_, 5-HT_NN and_CC mCPBG_NN ._SENT Lerisetron_NP is_VBZ the_DT only_JJ antagonist_NN tested_VBD that_IN shares_NNS a_DT binding_JJ site_NN interaction_NN in_IN this_DT region_NN with_IN agonists_NNS ._SENT In_IN contrast_NN to_TO 5-HT_NN and_CC mCPBG_NN ,_, however_RB ,_, lerisetron_NN also_RB interacts_VBZ with_IN Y152_NP as_RB indicated_VBD by_IN the_DT 190_CD fold_NN increase_NN in_IN Ki_NP on_IN Y152A_NP mutant_JJ receptors_NNS ._SENT Since_IN neither_DT d-tc_NP nor_CC [_SYM 3H]granisetron_JJ interacts_VBZ with_IN Y142_NP or_CC Y152_NP ,_, there_EX appears_VBZ to_TO be_VB a_DT difference_NN between_IN the_DT interactions_NNS formed_VBN by_IN these_DT antagonists_NNS compared_VBN to_TO lerisetron_NN ._SENT The_DT binding_JJ sites_NNS of_IN the_DT three_CD antagonists_NNS tested_VBN differ_VBP with_IN respect_NN to_TO this_DT binding_JJ loop_NN ._SENT Since_IN the_DT role_NN of_IN a_DT competitive_JJ antagonist_NN is_VBZ simply_RB to_TO block_VB the_DT binding_NN of_IN agonists_NNS and_CC prevent_VB channel_NN opening_NN ,_, the_DT specific_JJ amino_NN acids_NNS that_WDT interact_VBP with_IN the_DT ligand_NN can_MD vary_VB for_IN different_JJ antagonists_NNS ._SENT This_DT is_VBZ less_RBR likely_JJ to_TO be_VB the_DT case_NN with_IN agonists_NNS since_IN they_PP must_MD produce_VB a_DT conformational_JJ change_NN in_IN the_DT protein_NN to_TO exert_VB their_PP$ effects_NNS ._SENT Only_RB two_CD mutant_JJ receptors_NNS failed_VBN to_TO bind_NN [_SYM 3H]granisetron_JJ ;_: G147A_NP and_CC V149A_NP ._SENT G147_JJ is_VBZ the_DT conserved_VBN glycine_NN in_IN this_DT putative_JJ binding_JJ loop_NN ._SENT Chirara_NP et_FW ._SENT al._FW have_VBP suggested_VBN that_IN the_DT highly_RB conserved_VBN nature_NN of_IN the_DT glycine_NN in_IN this_DT region_NN may_MD indicate_VB the_DT existence_NN of_IN a_DT loop_NN structure_NN consisting_VBG of_IN either_DT gamma_NN or_CC a_DT loose_JJ three_CD residue-turn_NN in_IN the_DT nAChR_NN ._SENT Either_CC of_IN these_DT turns_NNS would_MD bring_VB the_DT two_CD putative_JJ beta-strands_NNS together_RB such_JJ that_IN gammaL109_JJ ,_, gammaY111_JJ and_CC gammaS115_JJ and_CC gammaY117_JJ are_VBP all_RB on_IN the_DT same_JJ side_NN of_IN an_DT antiparallel_JJ beta-sheet_NN ._SENT These_DT residues_NNS have_VBP been_VBN identified_VBN by_IN affinity_NN labeling_VBG ,_, site-directed_JJ mutagenesis_NN or_CC cysteine_NN substitution_NN to_TO lie_VB on_IN the_DT same_JJ surface_NN ._SENT A_DT classic_JJ 2-residue_JJ beta-turn_NN would_MD place_VB these_DT residues_NNS on_IN opposite_JJ surfaces_NNS ._SENT Substitution_NN of_IN the_DT conserved_VBN glycine_NN by_IN alanine_NN may_MD disrupt_VB the_DT structure_NN of_IN this_DT region_NN and_CC prevent_VB assembly_NN or_CC expression_NN of_IN the_DT receptor_NN ._SENT The_DT recent_JJ determination_NN of_IN the_DT crystal_NN structure_NN of_IN an_DT AChBP_NP supports_VBZ this_DT hypothesis_NN ._SENT The_DT AChBP_NP displays_VBZ a_DT large_JJ amount_NN of_IN homology_NN to_TO the_DT amino_NN terminal_NN of_IN LGIC_JJ receptors_NNS and_CC thus_RB may_MD be_VB similar_JJ in_IN structure_NN ._SENT The_DT crystal_NN structure_NN of_IN this_DT protein_NN reveals_VBZ a_DT loose_JJ 3_CD residue_NN turn_NN incorporating_VBG the_DT conserved_VBN glycine_NN residue_NN ._SENT Homologous_JJ residues_NNS in_IN other_JJ LGIC_JJ subunits_NN have_VBP also_RB been_VBN identified_VBN and_CC are_VBP shown_VBN in_IN Figure_NP ._SENT The_DT residues_NNS identified_VBN in_IN this_DT study_NN as_IN altering_VBG binding_JJ affinity_NN of_IN 5-HT3R_NN ligands_NNS would_MD also_RB be_VB present_JJ on_IN the_DT same_JJ surface_NN if_IN this_DT structure_NN is_VBZ present_JJ in_IN the_DT 5-HT3R_NN ._SENT While_IN Y140_NP lies_VBZ somewhat_RB outside_IN the_DT region_NN identified_VBN by_IN Chiara_NP in_IN the_DT nAChR_NN (_( homologous_JJ to_TO gammaN107_JJ )_) ,_, gammaL109_NN and_CC gammaL119_NN are_VBP homologous_JJ to_TO Y142_NP and_CC Y152_NP of_IN the_DT 5-HT3ASR_NN ._SENT The_DT ability_NN of_IN lerisetron_NN to_TO interact_VB with_IN both_DT Y142_NP and_CC Y152_NP also_RB supports_VBZ the_DT hypothesis_NN that_IN these_DT two_CD amino_NN acids_NNS are_VBP present_JJ in_IN a_DT loop_NN structure_NN since_IN the_DT eight_CD intervening_VBG residues_NNS would_MD position_VB Y142_NP and_CC Y152_NP too_RB far_RB apart_RB to_TO permit_VB them_PP both_CC to_TO interact_VB with_IN a_DT single_JJ ligand_NN even_RB if_IN they_PP were_VBD interacting_VBG with_IN functional_JJ groups_NNS on_IN opposite_JJ ends_NNS of_IN the_DT molecule_NN ._SENT A_DT loop_NN structure_NN would_MD bring_VB them_PP into_IN closer_JJR proximity_NN and_CC permit_VB interaction_NN with_IN the_DT small_JJ molecule_NN lerisetron_NN ._SENT All_DT three_CD tyrosine_NN mutations_NNS were_VBD investigated_VBN using_VBG a_DT whole_JJ cell_NN patch_NN clamp_NN assay_NN to_TO determine_VB if_IN functional_JJ changes_NNS could_MD be_VB observed_VBN ._SENT Whole_JJ cell_NN responses_NNS could_MD not_RB be_VB obtained_VBN for_IN Y140A_NP or_CC Y142A_NP ,_, although_IN specific_JJ binding_NN of_IN [_SYM 3H]granisetron_JJ was_VBD observed_VBN ._SENT These_DT data_NNS suggest_VBP that_IN ,_, while_IN the_DT receptors_NNS do_VBP assemble_VB and_CC are_VBP capable_JJ of_IN binding_NN [_SYM 3H]granisetron_JJ ,_, they_PP are_VBP either_RB not_RB transported_VBN to_TO the_DT cell_NN surface_NN or_CC are_VBP non-responsive_JJ to_TO 5-HT_JJ at_IN concentrations_NNS of_IN 1_CD mM_NNS or_CC less_JJR ._SENT Y152A_NP does_VBZ produce_VB functional_JJ channels_NNS however_RB they_PP display_VBP distinctly_RB altered_JJ response_NN kinetics_NNS when_WRB compared_VBN to_TO wildtype_NN receptors_NNS ._SENT Y152A_NP responses_NNS do_VBP not_RB show_VB the_DT rapid_JJ rise_NN times_NNS observed_VBD in_IN wt_NN receptors_NNS ._SENT The_DT extremely_RB slow_JJ rise_NN times_NNS observed_VBD for_IN Y152A_NP receptors_NNS may_MD indicate_VB a_DT change_NN in_IN rate_NN constants_NNS preceding_VBG channel_NN opening_NN ._SENT These_DT changes_NNS in_IN the_DT rate_NN constants_NNS for_IN either_DT agonist_NN binding_NN or_CC channel_NN opening_NN also_RB produce_VB a_DT 140_CD fold_NN decrease_NN in_IN the_DT observed_JJ EC50_NN for_IN 5-HT_JJ activation_NN ._SENT The_DT slow_JJ rise_NN is_VBZ followed_VBN by_IN a_DT non-desensitizing_VBG phase_NN of_IN the_DT response_NN that_WDT is_VBZ dramatically_RB different_JJ from_IN the_DT fast_JJ desensitization_NN observed_VBD for_IN wt_NN 5-HT3ASRs_NN ._SENT Lack_NN of_IN desensitization_NN could_MD result_VB from_IN either_CC a_DT stabilization_NN of_IN the_DT open_JJ state_NN of_IN the_DT channel_NN or_CC a_DT destabilization_NN of_IN the_DT desensitized_VBN state_NN ._SENT Mutations_NNS of_IN homologous_JJ or_CC nearby_JJ residues_NNS in_IN both_CC the_DT nAChR_NP and_CC GABAA_NP receptors_NNS have_VBP also_RB been_VBN demonstrated_VBN to_TO alter_VB the_DT agonist_NN response_NN ._SENT Mutation_NN of_IN the_DT homologous_JJ residue_NN in_IN the_DT GABAA_NP receptor_NN gamma-subunit_NN (_( T142_NP )_) to_TO serine_NN altered_VBD the_DT efficacy_NN of_IN the_DT agonist_NN Flumazenil_NP ,_, converting_VBG it_PP to_TO a_DT partial_JJ agonist_NN ._SENT In_IN the_DT nAChR_NN ,_, mutation_NN of_IN mouse_NN and_CC rat_NN epsilonP121_NN to_TO leucine_NN altered_VBD both_CC the_DT binding_NN of_IN acetylcholine_NN and_CC the_DT stability_NN of_IN the_DT open_JJ state_NN of_IN the_DT channel_NN ._SENT epsilonP121_NN is_VBZ homologous_JJ to_TO P154_NP in_IN the_DT 5-HT3R_NN and_CC is_VBZ only_RB two_CD residues_NNS away_RB from_IN Y152_NP ._SENT The_DT authors_NNS of_IN this_DT study_NN concluded_VBD that_IN this_DT portion_NN of_IN the_DT acetylcholine_NN binding_VBG site_NN was_VBD closely_RB linked_VBN to_TO the_DT channel_NN opening_NN region_NN of_IN the_DT receptor_NN ._SENT It_PP is_VBZ reasonable_JJ to_TO conclude_VB that_IN the_DT homologous_JJ region_NN in_IN the_DT 5-HT3R_NN may_MD perform_VB a_DT similar_JJ function_NN ._SENT The_DT link_NN between_IN an_DT agonist_NN binding_VBG domain_NN and_CC a_DT conformational_JJ change_NN leading_VBG to_TO channel_VB opening_NN is_VBZ not_RB unexpected_JJ since_IN the_DT two_CD must_MD obviously_RB be_VB linked_VBN ._SENT If_IN binding_VBG to_TO this_DT region_NN of_IN the_DT receptor_NN is_VBZ shown_VBN to_TO be_VB a_DT critical_JJ step_NN between_IN the_DT binding_NN of_IN agonists_NNS and_CC the_DT opening_NN of_IN the_DT channel_NN ,_, further_JJR investigation_NN of_IN the_DT amino_NN acids_NNS in_IN this_DT loop_NN may_MD provide_VB valuable_JJ clues_NNS to_TO molecular_JJ basis_NN of_IN this_DT process_NN ._SENT Our_PP$ data_NNS indicate_VBP an_DT important_JJ role_NN for_IN this_DT putative_JJ binding_JJ site_NN loop_NN in_IN the_DT interaction_NN of_IN the_DT 5-HT3R_NN with_IN different_JJ ligands_NNS and_CC illustrate_VBP the_DT difference_NN in_IN binding_VBG of_IN different_JJ structural_JJ classes_NNS of_IN ligands_NNS ._SENT Each_DT structural_JJ class_NN shows_VBZ different_JJ patterns_NNS of_IN interaction_NN with_IN amino_NN acids_NNS in_IN this_DT region_NN of_IN the_DT receptor_NN ._SENT [_SYM 3H]granisetron_NN does_VBZ not_RB appear_VB to_TO interact_VB with_IN any_DT of_IN the_DT amino_NN acids_NNS tested_VBN while_IN d-tc_NP interacts_VBZ with_IN only_JJ Y140_NP ,_, mCPBG_NN and_CC 5-HT_NN with_IN Y142_NP and_CC lerisetron_NN with_IN both_DT Y142_NP and_CC Y152_NP ._SENT Similar_JJ selective_JJ effects_NNS have_VBP been_VBN observed_VBN on_IN other_JJ residues_NNS including_VBG W183_NP ,_, W89_NP ,_, F107_NP and_CC E106_NP among_IN others_NNS ._SENT Our_PP$ data_NNS in_IN conjunction_NN with_IN those_DT of_IN other_JJ laboratories_NNS indicates_VBZ the_DT differences_NNS in_IN orientation_NN of_IN different_JJ ligands_NNS within_IN the_DT same_JJ binding_JJ cleft_NN ._SENT These_DT differences_NNS in_IN orientation_NN result_NN in_IN different_JJ amino_NN acid/functional_JJ group_NN interactions_NNS ._SENT As_IN the_DT structural_JJ detail_NN of_IN these_DT interactions_NNS emerges_VBZ ,_, these_DT differences_NNS could_MD potentially_RB be_VB exploited_VBN to_TO produce_VB more_RBR potent_JJ and_CC specific_JJ ligands_NNS ._SENT For_IN example_NN construction_NN of_IN a_DT "_`` hybrid_JJ "_'' ligand_NN that_WDT combines_VBZ the_DT interactions_NNS of_IN [_SYM 3H]granisetron_JJ with_IN those_DT of_IN d-tc_NP ,_, 5-HT_NN or_CC mCPBG_NN could_MD produce_VB an_DT antagonist_NN with_IN increased_VBN affinity_NN due_JJ to_TO the_DT additional_JJ binding_JJ energy_NN of_IN these_DT interactions_NNS and_CC a_DT greater_JJR specificity_NN since_IN it_PP would_MD utilize_VB more_RBR structural_JJ features_NNS of_IN the_DT binding_JJ site_NN ._SENT The_DT requirement_NN of_IN a_DT glycine_NN at_IN position_NN 147_CD and_CC the_DT ability_NN of_IN lerisetron_NN to_TO interact_VB with_IN both_DT Y142_NP and_CC Y152_NP also_RB support_VB the_DT hypothesis_NN that_IN the_DT secondary_JJ structure_NN in_IN this_DT region_NN of_IN the_DT receptor_NN is_VBZ formed_VBN by_IN a_DT loop_NN structure_NN ._SENT If_IN the_DT loose_JJ 3_CD residue_NN turn_NN proposed_VBN by_IN Chiara_NP et_FW ._SENT al._FW and_CC shown_VBN for_IN the_DT AChBP_NP is_VBZ present_JJ in_IN the_DT 5-HT3R_NN ,_, then_RB Y140_NP ,_, Y142_NP and_CC Y152_NP would_MD be_VB present_JJ on_IN the_DT same_JJ side_NN of_IN the_DT sheet_NN and_CC all_DT three_CD would_MD be_VB capable_JJ of_IN extending_VBG into_IN the_DT binding_JJ site_NN ._SENT A_DT similar_JJ observation_NN has_VBZ been_VBN made_VBN for_IN the_DT nAChR_NN where_WRB gammaS111_JJ ,_, gammaY117_JJ ,_, gammaL119_JJ ,_, deltaR113_NN and_CC deltaT119_NN of_IN the_DT mouse_NN nAChR_NN receptor_NN and_CC gammaL109_NN and_CC gammaY111_NN of_IN the_DT torpedo_NN nAChR_NN are_VBP all_RB thought_VBN to_TO be_VB present_JJ in_IN the_DT binding_JJ site_NN ._SENT Materials_NPS |_SYM [_SYM 3H]granisetron_JJ was_VBD purchased_VBN from_IN New_NP England_NP Nuclear_NP ,_, 5-HT_JJ from_IN Spectrum_NP ,_, and_CC mCPBG_NN and_CC d-tc_NN from_IN Research_NP Biochemical_NP International_NP ._SENT Lerisetron_NP was_VBD provided_VBN by_IN Dr._NP Karen_NP Kirschbaum_NP at_IN The_DT University_NP of_IN Louisiana_NP at_IN Monroe_NP ,_, Monroe_NP ,_, LA_NP ._SENT All_DT other_JJ reagents_NNS were_VBD obtained_VBN from_IN commercial_JJ sources_NNS ._SENT Site_NN directed_JJ mutagenesis_NN |_SYM Wild_NP type_NN 5-HT3AS_NP mouse_NN receptor_NN cDNA_NN was_VBD obtained_VBN from_IN Dr._NP Michael_NP White_NP ._SENT Mutant_JJ receptors_NNS were_VBD constructed_VBN using_VBG either_CC the_DT Quick_NP Change_NP Mutagenesis_NP kit_NN (_( Stratagene_NP )_) or_CC the_DT Altered_NP Sites_NP Mutagenesis_NP kit_NN (_( Promega_NP )_) ._SENT All_DT mutations_NNS were_VBD confirmed_VBN by_IN commercial_JJ DNA_NP sequencing_NP ._SENT Cell_NN culture_NN and_CC transfection_NN |_SYM tsA201_NN cells_NNS ,_, a_DT derivative_NN of_IN HEK293_NP cells_NNS ,_, were_VBD seeded_VBN at_IN a_DT density_NN of_IN 5_CD x_SYM 106_CD cells/100_NN mm_NN dish_NN ._SENT Cells_NNS were_VBD grown_VBN in_IN DMEM_NP medium_NN containing_VBG 10_CD %_NN FBS_NP ,_, 100_CD units/ml_NN penicillin/streptomycin_NN for_IN nine_CD hours_NNS in_IN 5_CD %_NN CO2_NN and_CC transfected_JJ with_IN 10_CD mug_NN mouse_NN 5-HT3ASR_NN cDNA_NN per_IN 100_CD mm_NN dish_NN using_VBG the_DT calcium_NN phosphate_NN technique_NN (_( New_NP Life_NP Technologies_NPS ,_, NY_NP )_) ._SENT Media_NNS was_VBD changed_VBN 12_CD --_: 14_CD hrs_NN after_IN transfection_NN ._SENT The_DT cells_NNS were_VBD allowed_VBN to_TO grow_VB for_IN another_DT 24_CD hours_NNS and_CC then_RB harvested_VBN ._SENT For_IN whole_JJ cell_NN patch_NN clamp_NN experiments_NNS ,_, tsA201_NN cells_NNS were_VBD seeded_VBN to_TO a_DT density_NN of_IN 0.25_CD x_SYM 106_CD cells/60_NN mm_NN dish_NN ._SENT Cells_NNS were_VBD grown_VBN in_IN DMEM_NP culture_NN medium_NN containing_VBG 10_CD %_NN FBS_NP and_CC 100_CD units/ml_NN penicillin/streptomycin_NN for_IN 12_CD hours_NNS prior_RB to_TO transfection_NN ._SENT Transfections_NNS were_VBD performed_VBN using_VBG Superfect_NP Transfection_NP Reagent_NP (_( Qiagen_NP ,_, CA_NP )_) ._SENT Ten_CD mug_NN of_IN cDNA_NN were_VBD mixed_VBN with_IN DMEM_NP medium_NN containing_VBG no_DT serum_NN or_CC antibiotics_NNS in_IN a_DT volume_NN of_IN 150_CD mul_NN ._SENT Twenty_CD mul_NN of_IN Superfect_NP reagent_NN were_VBD then_RB added_VBN and_CC the_DT mixture_NN incubated_VBN at_IN room_NN temperature_NN for_IN 15_CD min_NN ._SENT The_DT reaction_NN was_VBD terminated_VBN by_IN adding_VBG 1_CD ml_NN of_IN DMEM_NP medium_NN containing_VBG 10_CD %_NN FBS_NP and_CC 100_CD units/ml_NN penicillin/streptomycin_NN and_CC the_DT entire_JJ mixture_NN added_VBD to_TO cells_NNS in_IN the_DT 60_CD mm_NN dish_NN ._SENT Cells_NNS were_VBD exposed_VBN to_TO Superfect_NP Reagent_NP for_IN 3_CD hours_NNS ._SENT At_IN that_DT time_NN ,_, the_DT reagent_NN was_VBD replaced_VBN with_IN DMEM_NP medium_NN containing_VBG 10_CD %_NN FBS_NP and_CC 100_CD units/ml_NN penicillin/streptomycin_NN and_CC incubated_VBN for_IN an_DT additional_JJ 24_CD hours_NNS prior_RB to_TO use_VB ._SENT Binding_VBG assays_NNS |_SYM Transfected_JJ cells_NNS were_VBD scraped_VBN from_IN the_DT dishes_NNS ,_, washed_VBN twice_RB with_IN Dulbecco_NP 's_POS PBS_NP (_( New_NP Life_NP Technologies_NPS ,_, NY_NP )_) ,_, then_RB resuspended_JJ in_IN 1.0_CD ml_NN ice_NN cold_JJ PBS/100_NP mm_NN dish_NN ._SENT Cells_NNS were_VBD either_RB used_VBN fresh_JJ or_CC frozen_VBN at_IN this_DT step_NN until_IN needed_VBN ._SENT Immediately_RB prior_RB to_TO use_VB ,_, cells_NNS were_VBD homogenized_VBN on_IN ice_NN in_IN PBS_NP using_VBG a_DT glass_NN tissue_NN homogenizer_NN then_RB centrifuged_VBN at_IN 35_CD 000_CD x_SYM g_NN for_IN 30_CD minutes_NNS in_IN a_DT Beckman_NP JA20_NP rotor_NN (_( 4C_JJ )_) ._SENT Membranes_NNS were_VBD washed_VBN once_RB more_RBR with_IN PBS_NP at_IN 4C_NP then_RB resuspended_VBD in_IN 1_CD ml_NN PBS/100_JJ mm_NN dish_NN ._SENT Protein_NN content_NN was_VBD determined_VBN using_VBG a_DT Lowry_NP assay_NN (_( Sigma_NP ._SENT Diagnostics_NNS ,_, St._NP Louis_NP ,_, MO_NP )_) ._SENT Membranes_NNS were_VBD initially_RB prepared_VBN and_CC Bmax_NP and_CC Kd_NP values_NNS determined_VBN in_IN the_DT presence_NN and_CC absence_NN of_IN a_DT cocktail_NN of_IN protease_NN inhibitors_NNS (_( Complete_JJ Protease_NP Inhibitor_NP Cocktail_NP ,_, Roche_NP Diagnostics_NP ,_, Mannheim_NP Germany_NP )_) ._SENT No_DT change_NN in_IN Bmax_NP was_VBD observed_VBN as_IN a_DT result_NN of_IN omitting_VBG the_DT protease_NN inhibitor_NN (_( Bmax_NP (_( +_SYM protease_NN inhibitor)=_NN 3.1_CD +-_NN 0.11_CD pmoles/mg_NN protein_NN vs_NP Bmax_NP (_( -_: protease_NN inhibitor_NN )_) =_SYM 3.2_CD +-_NN 0.13_CD pmoles/mg_NN protein_NN ._SENT )_) hence_RB all_DT assays_NNS were_VBD performed_VBN in_IN the_DT absence_NN of_IN the_DT cocktail_NN ._SENT Binding_JJ assays_NNS were_VBD performed_VBN in_IN PBS_NP ._SENT For_IN Kd_NN determinations_NNS ,_, 100_CD mul_NN of_IN homogenate_NN was_VBD incubated_VBN at_IN 37C_JJ for_IN 1_CD hour_NN with_IN varying_VBG concentrations_NNS of_IN [_SYM 3H]granisetron_JJ (_( NEN_NP ,_, MA_NP )_) ._SENT Specific_JJ binding_NN of_IN [_SYM 3H]granisetron_JJ was_VBD determined_VBN as_IN the_DT bound_NN [_SYM 3H]granisetron_JJ not_RB displaced_VBN by_IN a_DT saturating_VBG concentration_NN of_IN a_DT competing_VBG ligand_NN ._SENT Kd_NN values_NNS were_VBD determined_VBN by_IN fitting_VBG the_DT binding_JJ data_NNS to_TO the_DT following_VBG equation_NN using_VBG Graphpad_NP PRISM_NP (_( San_NP Diego_NP CA_NP )_) :_: B_LS =_SYM Bmax_NP [_SYM L]n_NP /_SYM (_( [_SYM L]n_NP +_SYM Kn_NP )_) ,_, where_WRB B_NP is_VBZ bound_VBN ligand_NN ,_, Bmax_NP is_VBZ the_DT maximum_JJ binding_NN at_IN equilibrium_NN L_NP is_VBZ the_DT free_JJ ligand_NN concentration_NN and_CC n_NN is_VBZ the_DT Hill_NP coefficient_NN ._SENT Ki_NP determinations_NNS ,_, 100_CD mul_NN of_IN homogenate_NN was_VBD incubated_VBN at_IN 37C_JJ for_IN 2_CD hours_NNS with_IN varying_VBG concentrations_NNS of_IN inhi_NNS 